Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lyell Immunopharma (LYEL) Return on Sales (2020 - 2025)

Lyell Immunopharma (LYEL) has disclosed Return on Sales for 6 consecutive years, with 20828.0% as the latest value for Q4 2025.

  • Quarterly Return on Sales fell 298918.0% to 20828.0% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 7120.11% through Dec 2025, down 163344.0% year-over-year, with the annual reading at 7120.11% for FY2025, 163344.0% down from the prior year.
  • Return on Sales hit 20828.0% in Q4 2025 for Lyell Immunopharma, down from 2265.8% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 0.23% in Q4 2022 to a low of 21395.33% in Q3 2022.
  • Historically, Return on Sales has averaged 5298.25% across 5 years, with a median of 2171.6% in 2023.
  • Biggest five-year swings in Return on Sales: crashed -2137759bps in 2022 and later soared 1929809bps in 2023.
  • Year by year, Return on Sales stood at 16.73% in 2021, then soared by 99bps to 0.23% in 2022, then plummeted by -1721920bps to 4032.62% in 2023, then plummeted by -342bps to 17838.82% in 2024, then dropped by -17bps to 20828.0% in 2025.
  • Business Quant data shows Return on Sales for LYEL at 20828.0% in Q4 2025, 2265.8% in Q3 2025, and 5483.0% in Q2 2025.